Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study

To evaluate olaparib in advanced triple negative breast cancer (TNBC) patients with homologous recombination deficiency (HRD) and no germline BRCA1/2 mutations (gBRCA1/2mut). NOBROLA (NCT03367689) is a single-arm, open-label, multicenter, phase IIa trial, enrolling adult patients with advanced TNBC...

Full description

Bibliographic Details

Published in:	Breast (Edinburgh) Vol. 78; p. 103834
Main Authors:	Cortés, Alfonso, López-Miranda, Elena, Fernández-Ortega, Adela, Carañana, Vicente, Servitja, Sonia, Urruticoechea, Ander, Lema-Roso, Laura, Márquez, Antonia, Lazaris, Alexandros, Alcalá-López, Daniel, Mina, Leonardo, Gener, Petra, Rodríguez-Morató, Jose, Antonarelli, Gabriele, Llombart-Cussac, Antonio, Pérez-García, José, Cortés, Javier
Format:	Journal Article
Language:	English
Published:	Elsevier Ltd 01-12-2024 Elsevier
Subjects:	Germline BRCA1/2 mutations Homologous recombination deficiency Olaparib PARP inhibitors Short Communication Triple-negative breast cancer Olaparib Germline BRCA1/2 mutations Homologous recombination deficiency PARP inhibitors Triple-negative breast cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!